2021
DOI: 10.1080/19490976.2021.1900994
|View full text |Cite
|
Sign up to set email alerts
|

Understanding the relationship between norovirus diversity and immunity

Abstract: Human noroviruses are the most common viral cause of acute gastroenteritis worldwide. Currently, there are no approved vaccines or specific therapeutics to treat the disease. Some obstacles delaying the development of a norovirus vaccine are: (i) the extreme diversity presented by noroviruses; (ii) our incomplete understanding of immunity to noroviruses; and (iii) the lack of a robust cell culture system or animal model for human noroviruses. Recent advances in in vitro cultivation of norovirus, novel approach… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
23
0
1

Year Published

2021
2021
2025
2025

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(24 citation statements)
references
References 106 publications
0
23
0
1
Order By: Relevance
“…A low infectious dose and easily transmissibility make challenging to control the noroviruses burden [ 5 ]. However, efforts to develop noroviruses vaccines were hindered due to multiple factors [ 6 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…A low infectious dose and easily transmissibility make challenging to control the noroviruses burden [ 5 ]. However, efforts to develop noroviruses vaccines were hindered due to multiple factors [ 6 , 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…One of the major obstacles for norovirus vaccine development is the large viral genetic and antigenic diversity [10]. Genetic differences within VP1 have been used to classify noroviruses into genogroups and genotypes [11].…”
Section: Introductionmentioning
confidence: 99%
“…In Japan, the United States (US) and Europe, NoV accounts for 50% of all food-related illness (Thébault et al, 2021). Moreover, the global socioeconomic burden from NoV is estimated to be around 4.2 billion US Dollars (USD) (equivalent to 3.0 billion pounds) in direct health-care costs, with an additional 60.3 billion USD annually in indirect costs (equivalent to 47.8 billion pounds) (Ford-Siltz et al, 2021). NoV is estimated to cause 685 million cases and 210,000 deaths worldwide every year (Cannon et al, 2021;Cates et al, 2020;) .…”
Section: Introductionmentioning
confidence: 99%